ClinicalTrials.gg
CompletedNCT01185301CONCERTOUpdated Nov 15, 2013Results posted

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

A Phase 3 interventional study of adalimumab and methotrexate in Early Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-15.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
26th of 87
395 · median 160
Started
2010
with 3 others
Phase 3
36 of 87
1 open now
Registered
37th of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 26th largest by enrollment, is one of 4 that started in 2010, is one of 36 in phase 3, and was the 37th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).

03

Conditions studied

  • Early Rheumatoid Arthritis

Keywords

  • Arthritis
  • Erosion
  • Humira
  • Adalimumab
  • Injection
  • Rheumatoid
  • Methotrexate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects at least 18 years of age
  • Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987-revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider
  • Subject must meet the following criteria:

    1. Disease Activity Score of C-reactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline visit only)
    2. At least 6 swollen joints out of 66 assessed (at the Screening and Baseline visits)
    3. At least 8 tender joints out of 68 assessed (at the Screening and Baseline visits)
    4. C-reactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline visits)
    5. Fulfill at least one of the following three criteria: Rheumatoid Factor (RF) positive, have at least 1 bony erosion, anti-cyclic citrullinated peptide (anti-CCP) antibody positive
  • Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray (CXR), and a 12-lead (ECG) performed during Screening

Exclusion criteria

Exclusion Criteria:

  • Subject has previous exposure to any systemic biologic therapy including adalimumab
  • Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX)
  • Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study)
  • Subject has chronic arthritis diagnosed before age 17 years
  • History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active infection, (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)
  • virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR) qualitative test
  • Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline visit
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
395 participants (actual)

Study arms

  • Active comparator
    ADA + 2.5 mg MTX

    2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks

    Biological: adalimumab · Drug: methotrexate

  • Active comparator
    ADA + 5 mg MTX

    5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks

    Biological: adalimumab · Drug: methotrexate

  • Active comparator
    ADA + 10 mg MTX

    10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks

    Biological: adalimumab · Drug: methotrexate

  • Active comparator
    ADA + 20 mg MTX

    MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks

    Biological: adalimumab · Drug: methotrexate

Interventions

  • Biologicaladalimumab

    Pre-filled syringe every other week

    Also known as: Humira

  • weekly oral capsule dosing

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26

    Percentage of participants achieving low disease activity as defined by a clinical response (DAS28\[CRP\] \< 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants With DAS28(CRP) Remission at Week 26

    Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was \< 2.6 (DAS28\[CRP\] \< 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.

    Time frame: Week 26

  2. Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26

    Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

    Time frame: Baseline, Week 26

  3. Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26

    Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

    Time frame: Baseline, Week 26

  4. Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26

    Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

    Time frame: Baseline, Week 26

  5. Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26

    Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

    Time frame: Baseline, Week 26

  6. Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26

    Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

    Time frame: Baseline, Week 26

  7. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline, Week 26

  8. Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline, Week 26

  9. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26

    The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Week 26

  10. Percentage of Participants With No Radiographic Progression at Week 26

    "No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Week 26

  11. Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26

    SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, \> 3.4 to 11 = low disease activity, \> 11 to 26 = moderate disease activity, and \> 26 = high disease activity.

    Time frame: Week 26

  12. Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26

    CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity.

    Time frame: Week 26

07

Results

Posted Nov 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Started981009998
Completed83939389
Not completed15769
Withdrew: Adverse event3023
Withdrew: Withdrawal by subject7523
Withdrew: Lost to follow-up2001
Withdrew: Other reason3222

Outcome measures

PrimaryPercentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26

Percentage of participants achieving low disease activity as defined by a clinical response (DAS28\[CRP\] \< 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 2642.944.056.660.2
SecondaryPercentage of Participants With DAS28(CRP) Remission at Week 26

Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was \< 2.6 (DAS28\[CRP\] \< 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28(CRP) Remission at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With DAS28(CRP) Remission at Week 2627.632.037.444.9
SecondaryPercentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26

Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 2667.374.076.879.6
SecondaryPercentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26

Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 2645.951.053.562.2
SecondaryPercentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26

Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 2624.534.041.445.9
SecondaryPercentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26

Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 267.110.017.216.3
SecondaryPercentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26

Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment Questionnaire * Acute phase reactant value (C-reactive protein).

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 261.01.02.04.1
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26
units on a scaleADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26-0.72 ± 0.664-0.71 ± 0.717-0.78 ± 0.647-0.82 ± 0.698
SecondaryPercentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 2668.470.073.777.6
SecondaryChange From Baseline in Modified Total Sharp Score (mTSS) at Week 26

The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Week 26
Reported as:
Mean · score on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26
score on a scaleADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 260.9 ± 5.620.3 ± 1.920.4 ± 3.170.2 ± 2.22
SecondaryPercentage of Participants With No Radiographic Progression at Week 26

"No radiographic progression" was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With No Radiographic Progression at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With No Radiographic Progression at Week 2664.372.076.877.6
SecondaryPercentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26

SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, \> 3.4 to 11 = low disease activity, \> 11 to 26 = moderate disease activity, and \> 26 = high disease activity.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 2611.222.028.329.6
SecondaryPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26

CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 \[none\] to 10 \[severe\]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, \> 2.8 to 10 = low disease activity, \> 10 to 22 = moderate disease activity, and \> 22 = high disease activity.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26
percentage of participantsADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 2612.222.029.327.6

Adverse events

Collected over Treatment-emergent adverse events and serious adverse events, defined as those that began after the first dose of study drug, but within 70 days after the last dose of study drug. Duration of treatment was 24 weeks for ADA and 25 weeks for MTX.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADA + 2.5 mg MTX—5/98 (5.1%)24/98 (24.5%)
ADA + 5 mg MTX—2/100 (2%)26/100 (26%)
ADA + 10 mg MTX—3/99 (3%)34/99 (34.3%)
ADA + 20 mg MTX—7/98 (7.1%)41/98 (41.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders3/980/1001/990/98
ANAEMIABlood and lymphatic system disorders0/980/1001/991/98
ACUTE CORONARY SYNDROMECardiac disorders0/980/1000/991/98
ABDOMINAL PAINGastrointestinal disorders0/980/1000/991/98
COLITIS ULCERATIVEGastrointestinal disorders0/980/1000/991/98
INGUINAL HERNIAGastrointestinal disorders0/980/1000/991/98
ASTHENIAGeneral disorders1/980/1000/990/98
INTERVERTEBRAL DISC DEGENERATIONMusculoskeletal and connective tissue disorders0/980/1000/991/98
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/980/1000/990/98
HYPERTENSIONVascular disorders0/980/1000/991/98
Most frequent other events
Showing 10 of 11
Most frequent other events
EventADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTX
NAUSEAGastrointestinal disorders7/985/10013/998/98
NASOPHARYNGITISInfections and infestations3/986/1006/9911/98
HEADACHENervous system disorders4/986/1005/999/98
ALOPECIASkin and subcutaneous tissue disorders1/985/1006/998/98
ARTHRALGIAMusculoskeletal and connective tissue disorders6/982/1003/990/98
DIARRHOEAGastrointestinal disorders3/986/1006/993/98
FATIGUEGeneral disorders2/982/1006/994/98
DIZZINESSNervous system disorders4/980/1006/994/98
ABDOMINAL PAINGastrointestinal disorders0/980/1001/995/98
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/982/1003/995/98

Baseline characteristics

Age Continuous
Age Continuous(years)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
Mean52.0 ± 13.1949.7 ± 13.1452.1 ± 12.9453.8 ± 14.4151.9 ± 13.46
Age, Customized
Age, Customized(participants)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
< 65 years84898577335
> 65 years1411142160
Sex: Female, Male
Sex: Female, Male(Participants)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
Female70787874300
Male2822212495
28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP])
28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP])(scores on a scale)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
Mean6.10 ± 0.9216.22 ± 0.9435.86 ± 0.9715.91 ± 1.0146.02 ± 0.970
Modified Total Sharp Score (mTSS)
Modified Total Sharp Score (mTSS)(score)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
Mean9.79 ± 12.8498.60 ± 8.91210.76 ± 13.01710.55 ± 12.8529.92 ± 12.005
Health Assessment Questionnaire - Disability Index (HAQ-DI)
Health Assessment Questionnaire - Disability Index (HAQ-DI)(units on a scale)ADA + 2.5 mg MTXADA + 5 mg MTXADA + 10 mg MTXADA + 20 mg MTXTotal
Mean1.49 ± 0.7371.57 ± 0.6241.62 ± 0.6671.58 ± 0.6531.57 ± 0.670
08

Study locations

68 sites
  • Site Reference ID/Investigator# 38973
    Huntsville, Alabama 35801, United States
  • Site Reference ID/Investigator# 41962
    Mesa, Arizona 85202, United States
  • Site Reference ID/Investigator# 39260
    Phoenix, Arizona 85031, United States
  • Site Reference ID/Investigator# 45323
    Little Rock, Arkansas 72205, United States
  • Site Reference ID/Investigator# 38912
    Hemet, California 92543, United States
  • Site Reference ID/Investigator# 39673
    Victorville, California 92395, United States
  • Site Reference ID/Investigator# 38909
    Jacksonville, Florida 32209, United States
  • Site Reference ID/Investigator# 40422
    Miami, Florida 33169, United States
  • Site Reference ID/Investigator# 38910
    Sarasota, Florida 34239, United States
  • Site Reference ID/Investigator# 44284
    Atlanta, Georgia 30312, United States
  • Site Reference ID/Investigator# 38907
    Gainesville, Georgia 30501, United States
  • Site Reference ID/Investigator# 38972
    Lawrenceville, Georgia 30045, United States
  • Site Reference ID/Investigator# 39670
    Rock Island, Illinois 61201, United States
  • Site Reference ID/Investigator# 42282
    Springfield, Illinois 62704, United States
  • Site Reference ID/Investigator# 38911
    Wichita, Kansas 67203, United States
  • Site Reference ID/Investigator# 39672
    Covington, Louisiana 70433, United States
  • Site Reference ID/Investigator# 42204
    Omaha, Nebraska 68114, United States
  • Site Reference ID/Investigator# 40651
    Clifton, New Jersey 07012, United States
  • Site Reference ID/Investigator# 41422
    Freehold, New Jersey 07728, United States
  • Site Reference ID/Investigator# 41424
    Bronx, New York 10467, United States
  • Site Reference ID/Investigator# 40463
    Greenville, North Carolina 27834, United States
  • Site Reference ID/Investigator# 42202
    Columbus, Ohio 43213, United States
  • Site Reference ID/Investigator# 44282
    Norman, Oklahoma 73069, United States
  • Site Reference ID/Investigator# 41423
    Duncansville, Pennsylvania 16635, United States
  • Site Reference ID/Investigator# 38971
    Charleston, South Carolina 29406, United States
  • Site Reference ID/Investigator# 39666
    Jackson, Tennessee 38305, United States
  • Site Reference ID/Investigator# 39643
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 45325
    Dallas, Texas 75246, United States
  • Site Reference ID/Investigator# 52042
    Houston, Texas 77074, United States
  • Site Reference ID/Investigator# 40602
    Seattle, Washington 98101, United States
  • Site Reference ID/Investigator# 44924
    Buenos Aires, C1055AAF, Argentina
  • Site Reference ID/Investigator# 44926
    Buenos Aires, C1425DTG, Argentina
  • Site Reference ID/Investigator# 44925
    Rosario, Santa Fe, S2000PBJ, Argentina
  • Site Reference ID/Investigator# 47302
    San Juan, J5402DIL, Argentina
  • Site Reference ID/Investigator# 44928
    Graz, 80360, Austria
  • Site Reference ID/Investigator# 44930
    Vienna, 1090, Austria
  • Site Reference ID/Investigator# 44927
    Vienna, 1100, Austria
  • Site Reference ID/Investigator# 44934
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 44935
    Genk, 3600, Belgium
  • Site Reference ID/Investigator# 44933
    Gilly, 6060, Belgium
  • Site Reference ID/Investigator# 44932
    Liege, 4000, Belgium
  • Site Reference ID/Investigator# 43783
    Edmonton, T5M 0H4, Canada
  • Site Reference ID/Investigator# 43782
    Winnipeg, R3A 1M3, Canada
  • Site Reference ID/Investigator# 44937
    Brno, 63800, Czech Republic
  • Site Reference ID/Investigator# 48962
    Ceske Budejovice, 37021, Czech Republic
  • Site Reference ID/Investigator# 44939
    Ostrava, 72200, Czech Republic
  • Site Reference ID/Investigator# 44936
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 44938
    Uherske Hradiste, 686 01, Czech Republic
  • Site Reference ID/Investigator# 48963
    Zlin, 76001, Czech Republic
  • Site Reference ID/Investigator# 44945
    Berlin-Buch, 13125, Germany
  • Site Reference ID/Investigator# 44941
    Berlin, 10117, Germany
  • Site Reference ID/Investigator# 44942
    Munich, 80336, Germany
  • Site Reference ID/Investigator# 44944
    Ratingen, 40882, Germany
  • Site Reference ID/Investigator# 44943
    Zerbst, 39261, Germany
  • Site Reference ID/Investigator# 44946
    Bydgoszcz, 85168, Poland
  • Site Reference ID/Investigator# 44982
    Lodz, 90-242, Poland
  • Site Reference ID/Investigator# 46584
    Torun, 87-100, Poland
  • Site Reference ID/Investigator# 44984
    Warsaw, 02-118, Poland
  • Site Reference ID/Investigator# 44983
    Warsaw, 02-256, Poland
  • Site Reference ID/Investigator# 38975
    Caguas, 00725, Puerto Rico
  • Site Reference ID/Investigator# 40122
    San Juan, 00906-6312, Puerto Rico
  • Site Reference ID/Investigator# 39693
    San Juan, 00936-5067, Puerto Rico
  • Site Reference ID/Investigator# 38916
    San Juan, 00936-8344, Puerto Rico
  • Site Reference ID/Investigator# 39692
    Vega Baja, 00693, Puerto Rico
  • Site Reference ID/Investigator# 44947
    A Coruna, 15006, Spain
  • Site Reference ID/Investigator# 44987
    Elche (Alicante), 03203, Spain
  • Site Reference ID/Investigator# 44948
    Oviedo (Asturias), 33006, Spain
  • Site Reference ID/Investigator# 47782
    Valencia, 46026, Spain
09

References and documents

Publications

  • Goss SL, Klein CE, Jin Z, Locke CS, Rodila RC, Kupper H, Burmester GR, Awni WM. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clin Ther. 2018 Feb;40(2):309-319. doi: 10.1016/j.clinthera.2018.01.002. PubMed 29402521 ↗
  • Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017. PubMed 28955494 ↗
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2010
First posted
Aug 19, 2010
Start
Oct 2010
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Nov 15, 2013
Last update
Nov 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01185301
Responsible party
Sponsor
First posted
Aug 19, 2010
Start date
Oct 2010
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Nov 15, 2013
Last update
Nov 15, 2013

Study contacts

Dawn Carlson, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Methotrexate

Start the discussion